Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Declared competing interests of authors:John Gabbay is Director of the NCCHTA, but is not directly involved in setting research agendas. He is also a member of the editorial board for Health Technology Assessment, although was not involved in the editorial process for this report. JG is a member of the consumer involvement steering group at the NCCHTA and also is a member of INVOLVE, which promotes public involvement in the NHS, public health and social care research. Published October 2004This report should be referenced as follows: NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness...

Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan

“…Other genotypes (1a and 1b) were also found but their presence and circulation was rare but it was evident that resistance to anti-viral therapy was seen more in 1a and 1b genotypes (33% and 25%, respectively) as compared to other genotypes. Similar observation were noted by Shepherd et al (2004) that best sustained virological response (SVR) was seen for genotype 3 and 2 as compared to genotype 1. Micheal et al (2001) reported 42% SVR for genotype 1 and 80% SVR for genotype 2 and 3 in response to PEG-interferon alfa-2a (180µg) plus ribavirin therapy…”

The cost-effectiveness of testing for hepatitis C in former injecting drug users

“…42 Clinical trials in patients with moderate to severe disease have demonstrated overall sustained virological responses of 54% and 56% with 48 weeks of combination therapy. 43,44 Response rates are highest in patients with genotype 2 or 3, who have an 80% or greater chance of achieving a sustained virological response to treatment.…”

Letter: estimating the cost‐neutral price of sofosbuvir‐based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy

“…IFX was administered at a dose of 5 mg/kg in weeks 0, 2 and 6, and then about every 8 weeks; ADA was administered at a dose of 160 mg at entry, followed by 80 mg after 2 weeks, and then by 40 mg. Azathioprine at a dose of 2.5 mg/kg was also administered to all patients, and was suspended 6 months after starting anti--TNFa treatment, to reduce the risk of developing fatal complications. 4 All patients were treated with antibiotics (ciprofloxacin/metronidazole) for at least 1 month from the start of anti-TNFa therapy. Clinical assessment included CD activity by Harvey-Bradshaw index (HBI), 5 Perianal Disease Activity Index (PDAI), 6 inspection and digital examination (firm finger compression near the fistula's external opening).…”

“…The case of naive patients with genotype 1 is the most studied one, and has been evaluated for dual therapy [3][4][5][6] and previr-based triple therapies. 7,8 We have previously described a modified version 9 of…”

“…Shepherd's simulation model 4 to estimate the effectiveness of anti-HCV treatments. In the present analysis, we have firstly applied this model to the effectiveness of SBTT vs. dual therapy.…”